<DOC>
	<DOCNO>NCT01127620</DOCNO>
	<brief_summary>Double-blind phase : The objective study evaluate efficacy safety Bilastine 20 mg , compare Cetirizine placebo treatment perennial allergic rhinitis . Open-label Phase : The objective extension evaluate long-term safety Bilastine 20 mg one year symptomatic treatment perennial allergic rhinitis</brief_summary>
	<brief_title>Efficacy Study Symptomatic Treatment Perennial Allergic Rhinitis With 1 Year Safety Extension</brief_title>
	<detailed_description>Double-blind , randomize , placebo-controlled , parallel-group , international , multicenter study follow open label extension . Duration double-blind period 28 day duration open label period 12 additional month . The primary efficacy variable double-blind period area curve ( AUC ) total symptom scale ( TSS ) baseline ( define mean 6 last point patient ' diary randomization ) D28 visit accord patient 's assessment reflective symptom . 650 patient include study 614 complete double-blind phase . Out 614 patient complete double blind period , total 513 patient start open label period Bilastine 20 mg ( 83.6 % )</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Patients either sex age 12 70 year age Patients document clinical history PAR least 2 year prior study inclusion Positive skin prick test least one follow perennial allergen ( housedust mite , Dermatophagoides pteronyssinus D. farinae , animal dander , dog cat , mold , etc . ) Patients sum previous 6 assessment reflective nasal symptom score equal great 30 ( ≥30 72 ) . Additionally , time randomization patient positive symptomatology instantaneous nasal symptom equal great 5 ( ≥5 12 ) . Women childbearing potential negative pregnancy test use effective contraceptive method . Provision write informed consent participate willing attend require visit schedule protocol The criterion continue open label period include previous participation double blind period , eligibility longterm symptomatic treatment accord investigator assessment patient willingness follow treatment one year . Patients nonallergic rhinitis ( vasomotor , infectious , druginduced , etc. ) . Negative skin prick test ( define point 6.1.1. ) . Patients nasal polyp significant deviation nasal septum judge investigator well nasal intervention previous 6 month . Any nasal illness interfere aim study . Patients acute chronic sinusitis judge investigator . Patients also diagnose SAR ( seasonal allergic rhinitis ) , inclusion followup doubleblind phase study concurrent pollen season . Immunotherapy ( 6 month ) : In case patient immunotherapy treatment start 6 month prior start study , dos could modify study , dos could administer 24 hour study visit.. Patients take take specified medication prior randomisation study comply specify washout period Severe concomitant disease could interfere treatment response ( hepatic , renal , cardiovascular ) , electrocardiographic abnormality , arrhythmia , recent acute myocardial infarction neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Allergic Rhinoconjunctivitis</keyword>
	<keyword>Persistent allergic rhinitis</keyword>
	<keyword>Hay fever</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Sneezing</keyword>
	<keyword>Nasal congestion</keyword>
	<keyword>Rhinorrhea</keyword>
	<keyword>Nasal itch</keyword>
	<keyword>Ocular itching</keyword>
	<keyword>Ocular tearing</keyword>
	<keyword>Antihistamine</keyword>
</DOC>